-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

613.O2.6 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Long-term Outcomes in Clinically Defined Subgroups of Patients with Acute Myeloid Leukemia

Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, adult, epidemiology, Clinical Practice (Health Services and Quality), Translational Research, Clinical Research, health outcomes research, Diseases, patient-reported outcomes, real-world evidence, survivorship, Myeloid Malignancies, Human
Sunday, December 11, 2022: 12:00 PM-1:30 PM
271-273 (Ernest N. Morial Convention Center)
Moderators:
Lindsay Wilde, MD, Thomas Jefferson University and Brian A. Jonas, MD, PhD, University of California Davis School of Medicine
Disclosures:
Jonas: Rigel: Consultancy, Other: Travel Reimbursement; AbbVie: Consultancy, Other: Travel Reimbursement, Research Funding; GlycoMimetics: Consultancy, Other: protocol steering committee , Research Funding; Gilead: Consultancy, Other: data monitoring committee , Research Funding; BMS: Consultancy, Research Funding; 47: Research Funding; Genentech: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Servier: Consultancy; Takeda: Consultancy; Tolero: Consultancy; Treadwell: Consultancy; Accelerated Medical Diagnostics: Research Funding; Amgen: Research Funding; AROG: Research Funding; BMS: Consultancy, Research Funding; Celgene: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; F. Hoffmann-La Roche: Research Funding; Forma: Research Funding; Roche: Research Funding; Hanmi: Research Funding; Immune-Onc: Research Funding; Incyte: Research Funding; Loxo Oncology: Research Funding; LP Therapeutics: Research Funding; Pharmacyclics: Research Funding; Sigma Tau: Research Funding.
This session includes abstracts that summarize key clinical findings and longer term outcomes in clinically, histologically, and genomically defined subgroups of patients with acute myeloid leukemia.
12:00 PM

Fabio Efficace, PhD1*, Gerwin A. Huls, MD, PhD2, Michal Kicinski3*, Walter JFM Van Der Velden4, Richard Noppeney, MD5*, Sylvain Chantepie, MD6*, Laimonas Griskevicius, MD, PhD7*, Andreas Neubauer, MD8, Ernesta Audisio9*, Mario Luppi10*, Stephan Fuhrmann, M.D.11*, Robin Foà12*, Martina Crysandt, MD13*, Gianluca Gaidano, MD, PhD14, Radovan Vrhovac, MD, PhD15*, Adriano Venditti, MD16, Eduardus F.M. Posthuma, MD, PhD17, Anna Candoni, MD18*, Frederic Baron19, Olivier Legrand, MD, PhD20*, Andrea Mengarelli, MD21*, Marco Vignetti, MD1*, Anne Giraut, PhD3*, Corneel Coens3*, Stefan Suciu3*, P.W. Wijermans22 and Michael Luebbert, MD23

1Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy
2University Medical Center Groningen, Groningen, Netherlands
3EORTC Headquarters, Brussels, Belgium
4Department of Hematology, Radboud University Medical Centre, Nijmegen, Netherlands
5Klinik für Hämatologie, Universitätsklinikum Essen, Essen, Germany
6Institut d’Hématologie de Basse Normandie, Centre Hospitalier Universitaire de Caen, Caen, France
7Department of Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania
8Hematology, Oncology, Immunology, Philipps University, Marburg, Germany
9SC Ematologia Città della Salute e della Scienza Torino, Torino, Italy
10Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria, Modena, Italy
11Department of Hematology and Oncology, HELIOS Hospital Berlin-Buch, Berlin, Germany
12Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, "Sapienza" Università di Roma, Rome, Italy
13Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, Center for Integrated Oncology Aachen Bonn Cologne, Duesseldorf (CIO ABCD), Aachen, Germany
14Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy
15Department of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia
16Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
17Department of Internal Medicine, Reinier de Graaf Hospital, Delft, Netherlands
18Clinica Ematologica Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
19University of Liege, Liege, Belgium
20Service d'Hématologie Clinique et de Thérapie cellulaire, Hôpital Saint Antoine, APHP, Paris, France
21USOD Ematologia e Trapianti, IRCSS Istituto Nazionale Tumori Regina Elena, Roma, Italy
22Department of Hematology, Haga Teaching Hospital, The Hague, Netherlands
23Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany

12:15 PM

Jonathan Hyak, MD, MPH1*, Deedra Nicolet, MS2, Jessica Kohlschmidt, PhD3, Kellie J. Archer, PhD4*, James S. Blachly, MD5, Karilyn T. Larkin, MD6, Bayard L. Powell, MD7, Jonathan E. Kolitz, MD8, Maria R. Baer, MD9, William G. Blum, MD10, Geoffrey L. Uy, MD11, Wendy Stock, MD12, Richard M. Stone, MD13, John C. Byrd, MD14, Krzysztof Mrózek, MD, PhD15, Ann-Kathrin Eisfeld, MD2 and Alice S. Mims, MD5

1The Ohio State University, Columbus, OH
2Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University, Columbus, OH
3Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus
4Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, OH
5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
6Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH
7Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC
8Monter Cancer Center, North Shore University Hospital and Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY
9University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
10Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
11Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
12University of Chicago, Chicago, IL
13Center for Leukemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
14University of Cincinnati College of Medicine, Cincinnati, OH
15Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH

12:30 PM

Rimal Ilyas, MBBS1*, Isla McKerrow Johnson, MD1, Kristen McCullough, PharmD2, Aref Al-Kali, MD3, Hassan B. Alkhateeb, MD3*, Kebede Begna, MD4, Abhishek A. Mangaonkar, MBBS3, Mark R. Litzow, MD3, William J. Hogan, MB, BCh3, Mithun V. Shah, MD, PhD3, Mrinal M. M. Patnaik, MD, MBBS3, Animesh Pardanani, MBBS, PhD 3, Ayalew Tefferi, MD3 and Naseema Gangat, MBBS3

1Mayo Clinic, Rochester, MN
2Division of Pharmacology, Mayo Clinic, Rochester, MN
3Division of Hematology, Mayo Clinic, Rochester, MN
4Divison of Hematology, Mayo Clinic, Rochester, MN

12:45 PM

Filip Ionescu, MD1, David A. Sallman, MD2, Kendra Sweet, MD2, Rami S. Komrokji2, Onyee Chan, MD3, Andrew Kuykendall, MD4, Eric Padron, MD2, Rawan Faramand, MD5, Nelli Bejanyan, MD6, Farhad Khimani, MD5*, Hany Elmariah, MD, MS7, Joseph Pidala, MD, PhD7, Asmita Mishra, MD7, Lia Perez, MD7*, Taiga Nishihori, MD7 and Jeffrey E. Lancet, MD8,9

1Department of Hematology and Oncology, H. Lee Moffitt Cancer Center/University of South Florida, Tampa, FL
2Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
3Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
4Department of Malignant Hematology, H. Lee Mofitt Cancer Center, Tampa, FL
5Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
6Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
7Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
8Department of Malignant Hematology, H. Lee Moffitt Cancer Ctr. %26 Rsrch. Institute, Tampa, FL
9Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

1:00 PM

Sophia Gross1*, Jana Ihlow1,2*, Leonie Busack1*, Kacper Adamiak1*, Jens F. Schrezenmeier1*, Julia Jesse1*, Michaela Schwarz1*, Anne Floercken1*, Kathrin Rieger3*, Jan Krönke3*, Philipp le Coutre, MD4, Vivien Boldt5*, Ann-Christin von Bruenneck2*, David Horst2*, Thomas Burmeister1*, Igor Wolfgang Blau, MD6*, Ulrich Keller3*, Lars Bullinger, MD7 and Joerg Westermann1

1Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Clinic, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
2Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
3Department of Hematology, Oncology and Tumor Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
4Department of Hematology, Oncology and Tumor Immunology, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany
5Department of Tumor Cytogenetics, Labor Berlin - Charité Vivantes GmbH, Berlin, Germany
6Department of BMT, Clinic of Hematology, Oncology and Tumorimmunology, University Medicine Berlin, Berlin, Germany
7Department of Hematology, Oncology, and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

1:15 PM

Naveen Pemmaraju, MD1, Hagop Kantarjian, MD2, Joseph D. Khoury, MD, FCAP3, Nitin Jain, MD4, Muzaffar H Qazilbash, MD5, Sanam Loghavi, MD6, Sherry A. Pierce, BSN, BA1*, Keyur P. Patel, MBBS, PhD6, Guillermo Garcia-Manero, MD7, Elias Jabbour, MD1, Naval Daver, MD8, Gautam Borthakur, MD1 and Marina Konopleva, MD9*

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
3University of Nebraska Medical Center, Omaha, NE
4Department of Leukemia, MD Anderson Cancer Center, Houston, TX
5Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
8MD Anderson Cancer Center, Houston, TX
9Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

*signifies non-member of ASH